Q1 EPS Forecast for Cognition Therapeutics Cut by Analyst

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Stock analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Cognition Therapeutics in a research report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.12) for the quarter, down from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS and FY2026 earnings at ($0.28) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter in the prior year, the firm earned ($0.27) earnings per share.

CGTX has been the subject of several other research reports. Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Finally, Chardan Capital reduced their target price on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 21st. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.50.

Cognition Therapeutics Price Performance

Shares of Cognition Therapeutics stock opened at $0.44 on Wednesday. The firm has a market cap of $18.35 million, a PE ratio of -0.46 and a beta of 1.03. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The stock has a fifty day moving average price of $0.57 and a 200-day moving average price of $0.55.

Institutional Investors Weigh In On Cognition Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BIOS Capital Management LP bought a new position in Cognition Therapeutics during the fourth quarter worth about $4,208,000. Voss Capital LP bought a new stake in shares of Cognition Therapeutics in the fourth quarter valued at approximately $351,000. Sigma Planning Corp lifted its stake in shares of Cognition Therapeutics by 211.6% during the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after buying an additional 417,300 shares in the last quarter. Virtu Financial LLC bought a new position in Cognition Therapeutics in the 3rd quarter worth approximately $27,000. Finally, Two Sigma Investments LP grew its stake in Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after buying an additional 42,321 shares in the last quarter. 43.35% of the stock is currently owned by institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.